US · TNDM
Tandem Diabetes Care, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- San Diego, CA 92121
- Website
- tandemdiabetes.com
Price · as of 2025-12-31
$19.42
Market cap 1.72B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $45.08 | +132.13% |
| Intrinsic Value(DCF) | $10.09 | -48.04% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | $258.30 | $192.23 | $13,853,526.07 | $0.00 | $0.00 |
| 2014 | $134.70 | $53.88 | $0.00 | $0.00 | $0.00 |
| 2015 | $101.40 | $40.56 | $26,493.06 | $0.00 | $0.00 |
| 2016 | $22.00 | $8.80 | $1.16 | $0.00 | $0.00 |
| 2017 | $3.94 | $1.58 | $3.64 | $0.00 | $0.00 |
| 2018 | $64.52 | $60.15 | $1,462.69 | $0.00 | $0.00 |
| 2019 | $75.44 | $201.77 | $37,927.55 | $1.22 | $0.00 |
| 2020 | $88.34 | $66.71 | $17,525.14 | $3.19 | $0.00 |
| 2021 | $105.48 | $79.02 | $9,003.33 | $8.11 | $11.65 |
| 2022 | $37.63 | $52.34 | $916.27 | $0.00 | $0.00 |
| 2023 | $30.70 | $44.94 | $3.08 | $0.00 | $0.00 |
| 2024 | $17.96 | $51.86 | $29.71 | $0.00 | $0.00 |
| 2025 | $25.23 | $45.08 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Tandem Diabetes Care, Inc.'s (TNDM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $45.08
- Current price
- $19.42
- AI upside
- +132.13%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$10.09
-48.04% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TNDM | Tandem Diabetes Care, Inc… | $19.42 | 1.72B | +132% | -48% | — | — | -8.29 | 10.94 | 1.67 | -10.59 | -7.76 | 10.94 | 52.31% | -7.70% | -20.17% | -97.88% | -25.81% | -22.15% | 2.86 | -9.88 | 2.55 | 1.89 | -2.03 | 10680.00% | 793.00% | -69409.00% | -1.75% | -0.04 | -9.80% | 0.00% | 0.00% | 2.97% | -23.67 | -62.33 | 1.82 | 0.78 |
| EYPT | EyePoint Pharmaceuticals,… | $17.56 | 1.45B | +9,195% | -75% | — | — | -3.07 | 1.19 | 9.28 | -0.41 | -11.16 | 1.19 | 91.42% | -337.06% | -302.43% | -43.42% | 403.05% | -33.83% | 0.06 | -10418.14 | 7.81 | 7.57 | 0.60 | 2747.00% | -597.00% | 800187.00% | -32.46% | -2.57 | 360.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 1.21 | -0.07 |
| FTRE | Fortrea Holdings Inc. | $10.72 | 990.53M | +1% | -61% | — | — | -0.98 | 1.71 | 0.35 | -1.05 | -0.50 | -0.95 | 15.63% | -32.04% | -36.21% | -102.41% | -60.19% | -31.33% | 0.12 | -9.55 | 0.98 | 0.84 | 0.13 | 19455.00% | 100.00% | -6279.00% | 9.17% | 0.12 | 6.09% | 0.00% | 0.00% | 123.21% | -0.98 | 9.70 | 0.31 | -0.51 |
| IART | Integra LifeSciences Hold… | $11.38 | 886.41M | +457% | -63% | — | — | -1.55 | 0.77 | 0.49 | -1.58 | -0.02 | -1.13 | 51.69% | -30.17% | -31.58% | -39.90% | -21.27% | -13.52% | 0.21 | -5.72 | 2.54 | 1.19 | 0.04 | 736120.00% | 153.00% | -22439.00% | -3.88% | 0.11 | -1.46% | 0.00% | 0.00% | 219.53% | -1.53 | -24.24 | 0.46 | 0.59 |
| INMD | InMode Ltd. | $13.75 | 871.18M | +312% | -24% | +30% | -77% | 9.40 | 1.29 | 2.38 | 3.06 | — | 1.29 | 78.54% | 23.05% | 25.33% | 13.53% | 56.67% | 12.09% | 0.02 | — | 9.88 | 8.55 | -2.61 | -3644.00% | -616.00% | -3615.00% | 9.56% | 1.21 | 65.78% | 0.00% | 0.00% | 30.54% | 3.98 | 4.03 | 0.92 | 9.96 |
| KOD | Kodiak Sciences Inc. | $26.80 | 1.42B | — | — | — | — | -1.08 | 1.27 | — | -0.62 | — | 1.27 | 0.00% | — | — | -84.70% | -174.25% | -43.24% | 0.47 | — | 6.72 | 6.57 | 0.65 | -3260.00% | — | -3982.00% | -61.84% | -4.59 | -109.78% | 0.00% | 0.00% | 0.00% | -0.50 | -0.79 | — | -6.24 |
| NRIX | Nurix Therapeutics, Inc. | $15.97 | 1.38B | +65% | -49% | — | — | -5.52 | 2.71 | 17.39 | -3.77 | -93.55 | 2.71 | 77.55% | -340.16% | -314.90% | -49.63% | 1083.07% | -38.96% | 0.10 | — | 7.02 | 6.86 | 0.78 | 590.00% | 5395.00% | 4488.00% | -18.04% | -2.88 | 998.91% | 0.00% | 0.00% | 7.50% | -3.23 | -3.50 | 10.99 | 3.48 |
| PHAT | Phathom Pharmaceuticals, … | $12.56 | 979.85M | +275% | +76,266% | — | — | -3.78 | -1.91 | 4.77 | -4.45 | — | -1.91 | 87.09% | -91.36% | -126.35% | 63.97% | 57.00% | -69.41% | -0.01 | -2.35 | 1.73 | 1.58 | 0.80 | -4272.00% | 21693.00% | -3743.00% | -19.98% | -1.26 | 59.50% | 0.00% | 0.00% | 46.07% | -4.43 | -4.24 | 4.05 | -8.21 |
| SEPN | Septerna, Inc. | $29.02 | 1.3B | +1,403% | -60% | -79% | — | -0.89 | 0.15 | 59.16 | 3.30 | — | 0.15 | 100.00% | -7518.42% | -6678.88% | -37.62% | 815.26% | -24.45% | 0.06 | — | 27.77 | 27.40 | 2.68 | -2504845.00% | 61192.00% | 6724.00% | -109.39% | -5.25 | 706.65% | 0.00% | 0.00% | 215.10% | 3.24 | 3.76 | -243.58 | 1.00 |
| TNGX | Tango Therapeutics, Inc. | $11.14 | 1.23B | +109% | +24,801% | — | — | -1.68 | 1.10 | 5.22 | 0.01 | -16.54 | 1.10 | 100.00% | -346.09% | -309.73% | -57.58% | 436.15% | -36.24% | 0.18 | — | 6.98 | 6.76 | 0.23 | 1019.00% | 1517.00% | 1067.00% | -60.24% | -3.45 | 396.19% | 0.00% | 0.00% | 2.54% | 0.01 | 0.01 | -0.04 | -1.61 |
| URGN | UroGen Pharma Ltd. | $21.70 | 1.02B | -0% | -82% | — | — | -3.32 | -47.83 | 4.66 | -3.23 | — | -47.83 | 90.18% | -107.06% | -140.35% | 342.83% | 86.07% | -54.68% | -14.02 | -7.73 | 6.01 | 5.59 | 0.51 | -1662.00% | 929.00% | 2676.00% | -23.05% | -2.11 | 86.32% | 0.00% | 0.00% | 12.59% | -3.18 | -3.17 | 3.40 | -2.93 |
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
- CEO
- John F. Sheridan
- Employees
- 2.65K
- Beta
- 1.69
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($10.09 ÷ $19.42) − 1 = -48.04% (DCF, example).